Deka Bank Deutsche Girozentrale Collegium Pharmaceutical, Inc Transaction History

Deka Bank Deutsche Girozentrale

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$14.22 - $20.88 $217,850 - $319,881	-15,320 Reduced 43.37%	20,008 $349,000
Q1 2022 Apr 28, 2022	BUY	$17.2 - $22.5 $607,641 - $794,880	35,328 New	35,328 $708,000
Q4 2021 Feb 02, 2022	SELL	$17.5 - $21.35 $182,000 - $222,040	-10,400 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$15.78 - $20.82 $164,112 - $216,528	10,400 New	10,400 $204,000
Q3 2019 Nov 14, 2019	SELL	$10.16 - $13.28 $219,456 - $286,848	-21,600 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$10.62 - $16.59 $89,208 - $139,356	8,400 Added 63.64%	21,600 $286,000
Q1 2019 May 10, 2019	BUY	$13.58 - $18.72 $32,592 - $44,928	2,400 Added 22.22%	13,200 $221,000
Q4 2018 Feb 12, 2019	SELL	$14.78 - $19.68 $35,472 - $47,232	-2,400 Reduced 18.18%	10,800 $176,000
Q3 2018 Nov 09, 2018	SELL	$14.16 - $24.3 $4,248 - $7,290	-300 Reduced 2.22%	13,200 $0
Q1 2018 May 03, 2018	BUY	$18.15 - $29.21 $245,024 - $394,335	13,500 New	13,500 $338,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.